Novo Nordisk

Signal: Wegovy cuts cardiovascular risk by 20% for heart disease patients

Novo Nordisk’s blockbuster weight-loss drug Wegovy may reduce the risk of heart attack before the weight loss effects take place,…

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

Novo Nordisk, manufacturer of GLP-1 antagonist drugs Wegovy and Ozempic, now has a higher market capitalisation than the yearly GDP…